INCB161734 Clinical Trials (2026): 3 Studies for Solid Tumors & Healthy Participants
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 INCB161734 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Solid Tumors & Healthy Participants) and 1,361 total planned enrollment. 1 Phase 3 INCB161734 trial are listed. 2 INCB161734 clinical trials are actively recruiting at 26 U.S. sites across 14 states. Most recent activity: NCT07522073 (Mar 2029).
Where to Participate: All INCB161734 Trial Sites in the U.S. (26 sites across 14 states)
Every actively recruiting INCB161734trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AK | Investigative Site US016 | Anchorage99508 | NCT07522073 | Map |
| AZ | Mayo Clinic Hospital | Phoenix85054 | NCT06179160 | Map |
| CA | Stanford University | Palo Alto94305 | NCT06179160 | Map |
| CA | UCLA Healthcare Hematology-Oncology | Santa Monica90404 | NCT06179160 | Map |
| CO | Investigative Site US071 | Denver80218 | NCT07522073 | Map |
| CO | Sarah Cannon Research Institue At Healthone | Denver80218 | NCT06179160 | Map |
| FL | Investigative Site US072 | Fort Myers33901 | NCT07522073 | Map |
| FL | Florida Cancer Specialists | Sarasota34232 | NCT06179160 | Map |
| FL | Investigative Site US074 | St. Petersburg33701-4553 | NCT07522073 | Map |
| FL | Investigative Site US073 | West Palm Beach33401 | NCT07522073 | Map |
| IL | Investigative Site US009 | Springfield62702 | NCT07522073 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins | Baltimore21287 | NCT06179160 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06179160 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06179160 | Map |
| NY | Investigative Site US059 | Lake Success11042 | NCT07522073 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10022 | NCT06179160 | Map |
| NY | Weill Cornell Medicine | New York10021 | NCT06179160 | Map |
| PA | Jefferson University Hospitals | Philadelphia19107 | NCT06179160 | Map |
| TN | Investigative Site US060 | Nashville37203 | NCT07522073 | Map |
| TN | Scri Oncology Partners | Nashville37203 | NCT06179160 | Map |
| TX | Investigative Site US067 | Dallas75246 | NCT07522073 | Map |
| TX | Investigative Site US062 | Denison75020 | NCT07522073 | Map |
| TX | Md Anderson Cancer Center | Houston77030 | NCT06179160 | Map |
| TX | Investigative Site US063 | San Antonio78240 | NCT07522073 | Map |
| VA | Investigative Site US065 | Fairfax22031 | NCT07522073 | Map |
| VA | Investigative Site US064 | Salem24153 | NCT07522073 | Map |
INCB161734 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | 2 |
| P3 | 1 | 1 |
Recruiting INCB161734 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07522073 | DAWN-303A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | P3 | Solid Tumors | 588 | Apr 2026 |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | P1 | Solid Tumors | 710 | Jan 2024 |
INCB161734 clinical trials by indication
Solid Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07522073 | DAWN-303 | P3 | recruiting | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT06179160 | — | P1 | recruiting | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07018635 | — | P1 | completed | A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants |
INCB161734 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| DAWN-303 | NCT07522073 | P3 | recruiting | Solid Tumors | 588 | — |
All INCB161734 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07522073 | DAWN-303 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | P3 | recruiting | 588 | Incyte Corporation | Apr 2026 |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | P1 | recruiting | 710 | Incyte Corporation | Jan 2024 | |
| NCT07018635 | A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants | P1 | completed | 63 | Incyte Corporation | Jul 2025 |
INCB161734 clinical trials: frequently asked questions
- How many INCB161734 clinical trials are there?
- 3 INCB161734 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 1 is marked completed.
- Are INCB161734 clinical trials recruiting in 2026?
- Yes — 2 INCB161734 trials are actively recruiting in 2026, with 26 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is INCB161734 being studied for?
- INCB161734 is being studied for Solid Tumors, Healthy Participants. The trials are grouped by indication on this page.
- What phase is INCB161734 in?
- INCB161734 clinical trials span 1 Phase 3, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors INCB161734 clinical trials?
- The lead sponsor across the most INCB161734 trials is Incyte Corporation. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming INCB161734as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: